Have a personal or library account? Click to login
Botulinum Toxin Therapy for Cervical Dystonia: The Science of Dosing Cover

Botulinum Toxin Therapy for Cervical Dystonia: The Science of Dosing

Tremor and Other Hyperkinetic Movements
Volume 4 (2014): Issue 0
By: Virgilio Gerald H. Evidente and  Eric J. Pappert  
Open Access
|Nov 2014

References

  1. 1
    ChanJBrinMFFahnSIdiopathic cervical dystonia: Clinical characteristicsMov Disord1991611912610.1002/mds.8700602062057004
    Back to article
  2. 2
    JankovicJLederSWarnerDSchwartzKCervical dystonia: Clinical findings and associated movement disordersNeurology1991411088109110.1212/WNL.41.7.10882067638
    Back to article
  3. 3
    BrashearABotulinum toxin type A in the treatment of patients with cervical dystoniaBiologics200931719707390
    Back to article
  4. 4
    Epidemiological Study of Dystonia in Europe (ESDE) Collaborative GroupA prevalence study of primary dystonia in eight European countriesJ Neurol200024778779210.1007/s00415007009411127535
    Back to article
  5. 5
    JankovicJTsuiJBergeronCPrevalence of cervical dystonia and spasmodic torticollis in the United States general populationParkinsonism Relat Disord20071341141610.1016/j.parkreldis.2007.02.00517442609
    Back to article
  6. 6
    CamfieldLBen-ShlomoYWarnerTTImpact of cervical dystonia on quality of lifeMov Disord20021783884110.1002/mds.1012712210891
    Back to article
  7. 7
    SlawekJFriedmanAPotulskaAet alFactors affecting the health-related quality of life of patients with cervical dystonia and the impact of botulinum toxin type A injectionsFunct Neurol2007229510017637212
    Back to article
  8. 8
    MullerJKemmlerGWisselJet alThe impact of blepharospasm and cervical dystonia on health-related quality of life and depressionJ Neurol200224984284610.1007/s00415-002-0773-612140667
    Back to article
  9. 9
    Ben-ShlomoYCamfieldLWarnerTWhat are the determinants of quality of life in people with cervical dystonia?J Neurol Neurosurg Psychiatry20027260861410.1136/jnnp.72.5.60811971047
    Back to article
  10. 10
    TarsyDSimonDKDystoniaN Engl J Med200635581882910.1056/NEJMra05554916928997
    Back to article
  11. 11
    NeychevVKFanXMitevVIHessEJJinnahHAThe basal ganglia and cerebellum interact in the expression of dystonic movementBrain20081312499250910.1093/brain/awn16818669484
    Back to article
  12. 12
    ZoonsEBooijJNederveenAJDijkJMTijssenMAStructural, functional and molecular imaging of the brain in primary focal dystonia–a reviewNeuroimage2011561011102010.1016/j.neuroimage.2011.02.04521349339
    Back to article
  13. 13
    VidailhetMGrabliDRozeEPathophysiology of dystoniaCurr Opin Neurol20092240641310.1097/WCO.0b013e32832d9ef319512924
    Back to article
  14. 14
    SimpsonDMBlitzerABrashearAet alAssessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of NeurologyNeurology2008701699170610.1212/01.wnl.0000311389.26145.9518458230
    Back to article
  15. 15
    AlbaneseAAsmusFBhatiaKPet alEFNS guidelines on diagnosis and treatment of primary dystoniasEur J Neurol20111851810.1111/j.1468-1331.2010.03042.x20482602
    Back to article
  16. 16
    SwopeDBarbanoRTreatment recommendations and practical applications of botulinum toxin treatment of cervical dystoniaNeurol Clin200826Suppl 1546510.1016/S0733-8619(08)80005-918603168
    Back to article
  17. 17
    JankovicJBotulinum toxin in clinical practiceJ Neurol Neurosurg Psychiatry20047595195710.1136/jnnp.2003.03470215201348
    Back to article
  18. 18
    PoeweWDeuschlGNebeAet alWhat is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport. German Dystonia Study GroupJ Neurol Neurosurg Psychiatry199864131710.1136/jnnp.64.1.139436721
    Back to article
  19. 19
    HefterHKupschAMungersdorfMet alA botulinum toxin A treatment algorithm for de novo management of torticollis and laterocollisBMJ Open20111e00019610.1136/bmjopen-2011-000196
    Back to article
  20. 20
    BeneckeRDresslerDBotulinum toxin treatment of axial and cervical dystoniaDisabil Rehabil2007291769177710.1080/0142159070156826218033602
    Back to article
  21. 21
    JankovicJAdlerCHCharlesPDet alRationale and design of a prospective study: Cervical Dystonia Patient Registry for Observation of OnaBotulinumtoxinA Efficacy (CD PROBE)BMC Neurol20111114010.1186/1471-2377-11-14022054223
    Back to article
  22. 22
    ComellaCLThompsonPDTreatment of cervical dystonia with botulinum toxinsEur J Neurol200613Suppl 1162010.1111/j.1468-1331.2006.01440.x16417593
    Back to article
  23. 23
    CanoSJHobartJCFitzpatrickRBhatiaKThompsonAJWarnerTTPatient-based outcomes of cervical dystonia: A review of rating scalesMov Disord2004191054105910.1002/mds.2005515372595
    Back to article
  24. 24
    ZoonsEDijkgraafMGDijkJMvan SchaikINTijssenMABotulinum toxin as treatment for focal dystonia: A systematic review of the pharmaco-therapeutic and pharmaco-economic valueJ Neurol2012Dec259(12)25192610.1007/s00415-012-6510-x22552527
    Back to article
  25. 25
    DresslerDClinical presentation and management of antibody-induced failure of botulinum toxin therapyMov Disord200419Suppl 8S9210010.1002/mds.2002215027060
    Back to article
  26. 26
    KesslerKRSkuttaMBeneckeRLong-term treatment of cervical dystonia with botulinum toxin A: Efficacy, safety, and antibody frequency. German Dystonia Study GroupJ Neurol199924626527410.1007/s00415005034510367694
    Back to article
  27. 27
    BrashearABerganKWojcieszekJSiemersERAmbrosiusWPatients' perception of stopping or continuing treatment of cervical dystonia with botulinum toxin type AMov Disord20001515015310.1002/1531-8257(200001)15:1<;150::AID-MDS1024>3.0.CO;2-X10634256
    Back to article
  28. 28
    HsiungGYDasSKRanawayaRLafontaineALSuchowerskyOLong-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year periodMov Disord2002171288129310.1002/mds.1025212465070
    Back to article
  29. 29
    HaussermannPMarczochSKlingerCLandgrebeMConradBCeballos-BaumannALong-term follow-up of cervical dystonia patients treated with botulinum toxin AMov Disord20041930330810.1002/mds.1065915022184
    Back to article
  30. 30
    WisselJKanovskyPRuzickaEet alEfficacy and safety of a standardised 500 unit dose of Dysport (clostridium botulinum toxin type A haemaglutinin complex) in a heterogeneous cervical dystonia population: Results of a prospective, multicentre, randomised, double-blind, placebo-controlled, parallel group studyJ Neurol20012481073107810.1007/s00415017002812013585
    Back to article
  31. 31
    GelbDJYoshimuraDMOlneyRKLowensteinDHAminoffMJChange in pattern of muscle activity following botulinum toxin injections for torticollisAnn Neurol19912937037610.1002/ana.4102904071929208
    Back to article
  32. 32
    LangeOBigalkeHDenglerRWegnerFdeGrootMWohlfarthKNeutralizing antibodies and secondary therapy failure after treatment with botulinum toxin type A: Much ado about nothing?Clin Neuropharmacol20093221321810.1097/WNF.0b013e3181914d0a19620852
    Back to article
  33. 33
    CostaJEspirito-SantoCBorgesAet alBotulinum toxin type A therapy for cervical dystoniaCochrane Database Syst Rev2005CD00363315674910
    Back to article
  34. 34
    CostaJEspirito-SantoCBorgesAet alBotulinum toxin type B for cervical dystoniaCochrane Database Syst Rev2005CD00431515674941
    Back to article
  35. 35
    MerzPharmaceuticalsLLCXEOMIN® (incobotulinumtoxinA) for injection US Prescribing Information2011Version 07/2011
    Back to article
  36. 36
    MejiaNIVuongKDJankovicJLong-term botulinum toxin efficacy, safety, and immunogenicityMov Disord20052059259710.1002/mds.2037615645481
    Back to article
  37. 37
    JankovicJVuongKDAhsanJComparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystoniaNeurology2003601186118810.1212/01.WNL.0000055087.96356.BB12682332
    Back to article
  38. 38
    BrinMFComellaCLJankovicJLaiFNaumannMLong-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assayMov Disord2008231353136010.1002/mds.2215718546321
    Back to article
  39. 39
    NaumannMCarruthersACarruthersJet alMeta-analysis of neutralizing antibody conversion with onabotulinumtoxinA (BOTOX(R)) across multiple indicationsMov Disord2010Oct 1525132211810.1002/mds.2325420737546
    Back to article
  40. 40
    IpsenBiopharmLtdDysport® (abobotulinumtoxinA) for injection Prescribing Information2010Version 04/2010
    Back to article
  41. 41
    BeneckeRXeomin in the treatment of cervical dystoniaEur J Neurol200916Suppl 261010.1111/j.1468-1331.2009.02878.x20002740
    Back to article
  42. 42
    FrevertJXeomin is free from complexing proteinsToxicon20095469770119292989
    Back to article
  43. 43
    GoschelHWohlfarthKFrevertJet alBotulinum A toxin therapy: Neutralizing and nonneutralizing antibodies-therapeutic consequencesExp Neurol19971479610210.1006/exnr.1997.65809294406
    Back to article
  44. 44
    JoshiSGEliasMSinghAet alModulation of botulinum toxin-induced changes in neuromuscular function with antibodies directed against recombinant polypeptides or fragmentsNeuroscience201117920822210.1016/j.neuroscience.2011.01.03321277940
    Back to article
  45. 45
    ChinnapongseRBLewMFFerreiraJJet alImmunogenicity and long-term efficacy of botulinum toxin type B in the treatment of cervical dystonia: Report of 4 prospective, multicenter trialsClin Neuropharmacol20123521522310.1097/WNF.0b013e318263163c22932474
    Back to article
  46. 46
    GreenePFahnSDiamondBDevelopment of resistance to botulinum toxin type A in patients with torticollisMov Disord1994921321710.1002/mds.8700902168196686
    Back to article
  47. 47
    JankovicJSchwartzKResponse and immunoresistance to botulinum toxin injectionsNeurology1995451743174610.1212/WNL.45.9.17437675238
    Back to article
  48. 48
    DresslerDClinical features of antibody-induced complete secondary failure of botulinum toxin therapyEur Neurol200248262910.1159/00006495312138306
    Back to article
  49. 49
    ComellaCLJankovicJBrinMFUse of botulinum toxin type A in the treatment of cervical dystoniaNeurology200055S152111188979
    Back to article
  50. 50
    JankovicJBotulinum toxin therapy for cervical dystoniaNeurotox Res2006914514810.1007/BF0303393316785112
    Back to article
  51. 51
    AllerganIncBotox® (onabotulinumtoxinA) for injection, for intramuscular, intradetruser, or intradermal use US Prescribing Information2011Version 08/2011
    Back to article
  52. 52
    CharlesDBrashearAHauserRAet alEfficacy, tolerability, and immunogenicity of onabotulinumtoxina in a randomized, double-blind, placebo-controlled trial for cervical dystoniaClin Neuropharmacol20123520821410.1097/WNF.0b013e31826538c722948497
    Back to article
  53. 53
    TruongDDuaneDDJankovicJet alEfficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: Results of the first US randomized, double-blind, placebo-controlled studyMov Disord20052078379110.1002/mds.2040315736159
    Back to article
  54. 54
    TruongDBrodskyMLewMet alLong-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystoniaParkinsonism Relat Disord201014331335
    Back to article
  55. 55
    ComellaCLJankovicJTruongDDHanschmannAGrafeSEfficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN(R), botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystoniaJ Neurol Sci201130810310910.1016/j.jns.2011.05.04121764407
    Back to article
  56. 56
    FargelMPsailaEResults of a multi-national patient and physician survey on treatment satisfaction with current botulinum toxin treatment in focal dystonia (Abstract #980)Mov Disord201025S51110.1002/mds.22923
    Back to article
  57. 57
    SethiKDRodriguezROlayinkaBSatisfaction with botulinum toxin treatment: A cross-sectional survey of patients with cervical dystoniaJ Med Econ20121541942310.3111/13696998.2011.65372622208596
    Back to article
  58. 58
    BrashearAWattsMWMarchettiAMagarRLauHWangLDuration of effect of botulinum toxin type A in adult patients with cervical dystonia: A retrospective chart reviewClin Ther2000221516152410.1016/S0149-2918(00)83049-011192142
    Back to article
  59. 59
    EvidenteVGFernandezHHLeDouxMSet alA randomized, double-blind study of repeated incobotulinumtoxinA (Xeomin(®)) in cervical dystoniaJ Neural Transm20131201699170710.1007/s00702-013-1048-323779062
    Back to article
  60. 60
    EvidenteVGTruongDJankovicJet alIncobotulinumtoxinA (Xeomin®) injected for blepharospasm or cervical dystonia according to patient needs is well toleratedJ Neurol Sci2014Aug 10. pii: S0022-510X(14)00517-610.1016/j.jns.2014.08.004
    Back to article
  61. 61
    JankovicJAdlerCHCharlesPDet alCervical dystonia patient registry for observation of Botox efficacy (CD PROBE): Interim results of physician-reported outcomesPoster presented at 63rd Annual Meeting of the American Academy of NeurologyApril 9–16 (Honolulu, HI)2011http://www.bcm.edu/neurology/pdf/poster_pdcmdc_CD-PROBE5.pdf.Accessed October 9, 2012
    Back to article
DOI: https://doi.org/10.5334/tohm.185 | Journal eISSN: 2160-8288
Journal RSS Feed
Language: English
Submitted on: Oct 25, 2012
Accepted on: Sep 24, 2014
Published on: Nov 12, 2014
Published by: Columbia University Libraries/Information Services
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year
Keywords:
AbobotulinumtoxinA,
incobotulinumtoxinA,
onabotulinumtoxinA,
rimabotulinumtoxinB,
cervical dystonia

© 2014 Virgilio Gerald H. Evidente, Eric J. Pappert, published by Columbia University Libraries/Information Services
This work is licensed under the Creative Commons License.

Previous articleVolume 4 (2014): Issue 0Next article